查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1736514

全球肽類癌症疫苗市場規模（按類型、技術、應用、區域範圍和預測）

Global Peptide Cancer Vaccine Market Size By Type, By Technology, By Application, By Geographic Scope And Forecast
出版日期: | 出版商: Verified Market Research | 英文 | 商品交期: 2-3個工作天內

價格
簡介目錄

肽類癌症疫苗的市場規模及預測

2024 年胜肽癌症疫苗市場規模價值 8.9085 億美元，預計到 2032 年將達到 33.3704 億美元，預測期內（2026-2032 年）的複合年成長率為 19.80%。

全球肽類癌症疫苗市場正經歷強勁成長，這得益於癌症患者數量的增加、技術進步、新型癌症療法的研發、政府支持的增加、老齡人口的擴大以及肽類癌症疫苗的長期影響和選擇性。近三分之一的癌症死亡病例歸因於吸菸、高體重指數、飲酒、水果和蔬菜攝取量低以及缺乏體能活動。因此，預防和治療癌症所需的癌症疫苗需求很高，這推動了胜肽類癌症疫苗市場的領先。全球肽類癌症疫苗市場報告對市場進行了全面評估，全面分析了關鍵細分市場、趨勢、市場促進因素、限制因素、競爭格局以及在市場中發揮關鍵作用的因素。

推動全球胜肽類癌症疫苗市場的因素

胜肽癌症疫苗市場的市場促進因素可能受到多種因素的影響，其中包括：

癌症發生率不斷上升：癌症發生率不斷上升：全球癌症發生率持續上升，對疫苗接種等有效癌症治療的需求也隨之增加。

免疫療法的發展：包括癌症疫苗在內的免疫療法因其個人化標標靶治療的前景，近年來引起了廣泛的興趣。

人們對精準醫療的興趣日益濃厚：胜肽類癌症疫苗是精準醫療運動的一個組成部分，精準醫療旨在根據每位患者的基因組成和癌症的具體特徵為其客製化治療方案。

技術發展：胜肽合成、疫苗傳遞方法和生物資訊學的進步都在提高胜肽癌症疫苗的功效和發展，增強其作為治療選擇的潛力。

資金籌措：公共和私營部門對癌症疫苗研發的資金增加正在促進基於胜肽的疫苗的製造和商業化。

有利的法規環境：監管機構對癌症疫苗前景的認可度不斷提高，這些尖端治療方法的許可程序也得到簡化，並有望擴大市場。

醫療支出不斷上漲：隨著全球醫療成本不斷上漲，人們和醫療專業人員更願意考慮胜肽癌症疫苗等尖端治療方法。

夥伴關係和協作：研究中心、生物技術公司和製藥公司正在共同努力促進創新並加速胜肽癌症疫苗的研發和廣泛分發。

提高意識和接受度：隨著患者和醫療保健提供者對癌症疫苗的了解不斷增加以及採取更積極的醫療管理措施，胜肽癌症疫苗正變得越來越廣泛地被接受。

聯合治療潛力：胜肽類癌症疫苗與放射線治療、化療、查核點抑制劑等其他癌症治療方法合併使用時，療效較佳，具有巨大的市場潛力。

限制全球胜肽類癌症疫苗市場的因素

多種因素可能會對胜肽癌症疫苗市場造成限制和挑戰，其中一些因素如下：

開發成本高：胜肽類癌症疫苗的研發成本很高，包括臨床試驗、生產製造、監管核准程序等成本。如此高的價格可能會阻礙投資並阻礙疫苗技術的進步。

疫苗設計的複雜性：成功設計胜肽類癌症疫苗需要對腫瘤抗原和免疫反應有透徹的了解。選擇正確抗原的難度可能會顯著延遲個人化疫苗的研發進程。

監管障礙：新疫苗的監管核准流程複雜且耗時。肽類癌症疫苗必須經過廣泛的測試，以證明其安全性、有效性和生產一致性，這可能會推遲其上市。

療效有限：胜肽類癌症疫苗作為一種客製化治療方法很有前景，但患者對癌細胞產生強烈而持久的免疫反應的能力各不相同，並且在許多癌症類型和患者群體中仍然難以實現一致的療效。

與其他治療方法的競爭：免疫查核點抑制劑、放射線治療、化療、標靶治療等是一些胜肽類癌症疫苗必須與之競爭的癌症治療方法。由於這些治療方法已確立的市場地位和已證明的優勢，胜肽類疫苗可能難以廣泛應用。

可近性和可負擔性：高昂的醫療費用、醫療基礎設施的缺乏以及報銷問題可能會限制當地獲得胜肽疫苗。疫苗業務要發展壯大，至關重要的是確保各地患者都能獲得疫苗，並且負擔得起。

安全性問題：胜肽癌症疫苗的採用可能會受到安全問題的影響，包括潛在的副作用和自體免疫反應，需要透過嚴格的疫苗設計和臨床試驗來解決這些問題，以獲得醫生和患者的信任。

智慧財產權問題：胜肽類癌症疫苗的相關權利可能引發智慧財產權糾紛，阻礙該領域的合作與發展。促進相關人員之間的合作並消除智慧財產權障礙對於市場擴張至關重要。

目錄

第1章 胜肽類癌症疫苗的全球市場介紹

  • 市場概覽
  • 研究範圍
  • 先決條件

第2章執行摘要

第3章：已驗證的市場研究調查方法

  • 資料探勘
  • 驗證
  • 第一手資料
  • 資料來源列表

第4章全球胜肽癌症疫苗市場展望

  • 概述
  • 市場動態
    • 驅動程式
    • 限制因素
    • 機會
  • 波特五力模型
  • 價值鏈分析

第5章全球胜肽類癌症疫苗市場（依技術）

  • 概述
  • 重組癌症疫苗
  • 全細胞癌症疫苗
  • 病毒載體和DNA癌症疫苗
  • 其他技術（樹突細胞、抗原等）

第6章全球胜肽癌症疫苗市場（按應用）

  • 概述
  • 乳癌
  • 肺癌
  • 黑色素瘤
  • 攝護腺癌
  • 其他

第7章全球胜肽癌症疫苗市場（按類型）

  • 概述
  • 個性化胜肽疫苗
  • 肽脈衝樹突狀細胞癌症疫苗
  • 胜肽雞尾酒類型
  • 多效價肽疫苗
  • 其他

第8章全球胜肽類癌症疫苗市場（按地區）

  • 概述
  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 德國
    • 英國
    • 法國
    • 其他歐洲國家
  • 亞太地區
    • 中國
    • 日本
    • 印度
    • 其他亞太地區
  • 其他
    • 拉丁美洲
    • 中東和非洲

第9章全球胜肽類癌症疫苗市場的競爭格局

  • 概述
  • 各公司市場排名
  • 重點發展策略

第10章 公司簡介

  • OSE Immunotherapeutics
  • GlaxoSmithKline PLC
  • Moderna Inc.
  • Merck and Co Inc.
  • F Hoffmann-La Roche AG
  • BrightPath BIoTherapeutics
  • Boston Biomedical
  • VAXON BIoTech
  • Generex BIoTechnology
  • ISA Pharmaceuticals

第11章 重大進展

  • 產品發布/開發
  • 合併與收購
  • 業務擴展
  • 夥伴關係與合作

第12章 附錄

  • 相關調查
簡介目錄
Product Code: 37296

Peptide Cancer Vaccine Market Size And Forecast

Peptide Cancer Vaccine Market size was valued at USD 890.85 Million in 2024 and is projected to reach USD 3337.04 Million by 2032, growing at a CAGR of 19.80% during the forecast period 2026-2032.

The Global Peptide Cancer Vaccine Market has witnessed strong growth owing to a rise in the number of cancer patients, technological advancements, new cancer drug advances, increasing government aid, the expanding older population, and the peptide cancer vaccine's long-term impact and selectivity. Almost one-third of cancer deaths are caused by tobacco use, a high BMI, alcohol use, a low fruit and vegetable intake, and a lack of physical exercise. As a result, there is a high need for cancer vaccines to prevent and cure cancer, moving the market for peptide cancer vaccines ahead. The Global Peptide Cancer Vaccine Market report provides a holistic evaluation of the market. The report offers a comprehensive analysis of key segments, trends, drivers, restraints, competitive landscape, and factors that are playing a substantial role in the market.

Global Peptide Cancer Vaccine Market Drivers

The market drivers for the Peptide Cancer Vaccine Market can be influenced by various factors. These may include:

Growing Cancer Incidence: As cancer rates continue to rise worldwide, there is an increasing need for cancer treatments that work, such as vaccinations.

Developments in Immunotherapy: With its promise to provide individualised and targeted treatment choices, immunotherapy, including cancer vaccines, has received a lot of interest in recent years.

Increasing Interest in Precision Medicine: Peptide cancer vaccines are a component of the larger movement in precision medicine, which attempts to customise care for each patient according to their genetic composition and unique cancer traits.

Technological developments: Peptide synthesis, vaccine delivery methods, and bioinformatics have all advanced, improving the efficacy and development of peptide cancer vaccines and raising their prospects as a therapeutic option.

funding in Research and Development: The creation and commercialization of peptide-based vaccinations have been expedited by increased public and private sector funding in the study and development of cancer vaccines.

Positive Regulatory Environment: As a result of regulatory bodies' growing recognition of the promise of cancer vaccines and their streamlining of the licencing procedures for these cutting-edge therapies, the market is poised to expand.

Growing Healthcare Expenditure: As healthcare costs rise globally, people and healthcare professionals are becoming more open to investigating cutting-edge therapy options such peptide cancer vaccines.

Partnerships and Collaborations: Research centres, biotechnology companies, and pharmaceutical corporations are working together to promote innovation and hasten the creation and broader distribution of peptide cancer vaccines.

Growing Awareness and Acceptance: Peptide cancer vaccines are becoming more widely accepted as a result of increased patient and healthcare professional knowledge about cancer vaccines as well as a move towards proactive healthcare management.

Possibility for Combination Therapies: Peptide cancer vaccines can be more effective and have a larger market potential when used in conjunction with other cancer treatments such radiation therapy, chemotherapy, and checkpoint inhibitors.

Global Peptide Cancer Vaccine Market Restraints

Several factors can act as restraints or challenges for the Peptide Cancer Vaccine Market. These may include:

High Development Costs: Peptide cancer vaccines have high research and development costs, including expenses for clinical trials, production, and regulatory approval procedures. These expensive prices may discourage investment and impede the advancement of vaccine technology.

Complexity of Vaccine Design: A thorough understanding of tumour antigens and immune responses is necessary to design successful peptide cancer vaccines. The process of developing vaccines that are customised for each patient can be slowed significantly by the difficulties involved in selecting appropriate antigens.

Regulatory Obstacles: The approval procedures for new vaccinations under regulation can be difficult and time-consuming. To prove safety, efficacy, and manufacturing consistency, peptide cancer vaccines must go through extensive testing, which may cause a delay in their release onto the market.

Limited Efficacy: Peptide cancer vaccines show promise as a customised therapeutic approach, but patient-to-patient variability exists in their ability to mount a strong and long-lasting immune response against cancer cells. It is still difficult to achieve consistent efficacy across many cancer types and patient demographics.

Competition from Other Therapies: Immune checkpoint inhibitors, radiation therapy, chemotherapy, and targeted therapies are some of the cancer treatment methods that peptide cancer vaccines must contend with. It may be difficult for peptide vaccines to become widely used due to the established market positions and shown benefits of these treatments.

Accessibility and affordability: High expenses, a dearth of healthcare infrastructure, and problems with reimbursement may restrict a region's capacity to obtain peptide cancer vaccines. For the vaccine business to expand, it is imperative that vaccinations remain accessible and affordable for patients everywhere.

Safety Concerns: Adoption of peptide cancer vaccines may be impacted by safety concerns, which include possible adverse effects and autoimmune reactions. Gaining the trust of doctors and patients requires addressing safety concerns through meticulous vaccine design and clinical testing.

Intellectual Property Problems: Rights to peptide cancer vaccines may give rise to intellectual property conflicts that impede cooperation and progress in the field. Promoting cooperation among stakeholders and removing obstacles related to intellectual property are crucial for expanding the market.

Global Peptide Cancer Vaccine Market: Segmentation Analysis

The Global Peptide Cancer Vaccine Market is segmented on the basis of Type, Technology, Application, And Geography.

Peptide Cancer Vaccine Market, By Type

  • Personalized Peptide Vaccine
  • Peptide-Pulsed Dendritic Cancer Vaccine
  • Peptide Cocktail Type
  • Multivalent Peptide Vaccine
  • Others

Based on Type, The market is segmented into Personalized Peptide Vaccine, Peptide-Pulsed Dendritic Cancer Vaccine, Peptide Cocktail Type, Multivalent Peptide Vaccine, and Others. The Peptide-Pulsed Dendritic Cancer Vaccine segment holds the largest market share during the forecast period. With the application of the Peptide-Pulsed Dendritic Cancer Vaccine, most of the problems associated with cancer immunotherapy are expected to be resolved.

Peptide Cancer Vaccine Market, By Technology

  • Recombinant Cancer Vaccines
  • Whole-cell Cancer Vaccines
  • Viral Vector and DNA Cancer Vaccines
  • Other Technologies (Dendritic Cells, Antigen, etc.)

Based on Technology, The market is segmented into Recombinant Cancer Vaccines, Whole-cell Cancer Vaccines, Viral Vector and DNA Cancer Vaccines, and Other Technologies (Dendritic Cells, Antigen, etc.). The Recombinant Cancer Vaccines sector now leads the worldwide market and is projected to do so for the foreseeable future. This is due to the enormous number of cancer vaccinations that have been licensed utilizing recombinant technology. This comprises inserting DNA encoding an antigen into mammalian cells that activates an immune reaction, expressing the antigen in these cells, and then extracting it from them.

Peptide Cancer Vaccine Market, By Application

  • Breast Cancer
  • Lung Cancer
  • Melanoma
  • Prostate Cancer
  • Others

Based on Application, The market is segmented into Breast Cancer, Lung Cancer, Melanoma, Prostate Cancer, and Others. The Prostate Cancer segment is estimated to witness the highest CAGR during the forecast period. The factors that can be attributed to the rise in demand for Provenge (prostate cancer vaccine) along with the increase in the number of prostate cancer vaccines in the pipeline are fueling the demand for this segment.

Peptide Cancer Vaccine Market, By Geography

  • North America
  • Europe
  • Asia Pacific
  • Rest of the World
  • On the basis of Regional Analysis, The Global Peptide Cancer Vaccine Market is classified into North America, Europe, Asia Pacific, and the Rest of the world. The Peptide Cancer Vaccine Market is expected to have the most growth in North America. The presence of a significant number of biotech and pharmaceutical participants in this area is supporting the demand for the Peptide Cancer Vaccine Market. Furthermore, the increased occurrence of cancer is fueling the growth of the Peptide Cancer Vaccine Market in this area. During the projected period, Asia Pacific is expected to be the fastest-expanding region in the Peptide Cancer Vaccine Market. This increase might be attributed to the region's growing research activity. These research endeavors improve access and promote cost-effective operational efficiency.

Key Players

The "Global Peptide Cancer Vaccine Market" study report will provide a valuable insight with an emphasis on the global market including some of the major players such as Boston Biomedical, VAXON Biotech, TapImmune, Sellas, ISA Pharmaceuticals, Generex Biotechnology, Immatics, OncoTherapy Science, BrightPath Biotherapeutics, Enzo Life Science, OSE Immunotherapeutics, GlaxoSmithKline PLC, Moderna Inc., Merck and Co Inc., F Hoffmann-La Roche AG, Galena Biopharma, Agenus Inc., BioNTech SE, Genexine Inc., Phosplatin Therapeutics, Provectus Biopharmaceuticals, Inc.

Our market analysis also entails a section solely dedicated to such major players wherein our analysts provide an insight into the financial statements of all the major players, along with its product benchmarking and SWOT analysis. The competitive landscape section also includes key development strategies, market share, and market ranking analysis of the above-mentioned players globally.

Key Developments

  • In December 2021, in an educational session at the ESMO Immune-Oncology Congress 2021, ISA Pharmaceuticals discussed critical learnings in cancer vaccine development.
  • In November 2019, new results from a phase 1 study testing DSP-7888, an experimental WT1 cancer peptide vaccine, in patients with advanced malignancies, were presented by Boston Biomedical, Inc.

TABLE OF CONTENTS

1 INTRODUCTION OF GLOBAL PEPTIDE CANCER VACCINE MARKET

  • 1.1 Overview of the Market
  • 1.2 Scope of Report
  • 1.3 Assumptions

2 EXECUTIVE SUMMARY

3 RESEARCH METHODOLOGY OF VERIFIED MARKET RESEARCH

  • 3.1 Data Mining
  • 3.2 Validation
  • 3.3 Primary Interviews
  • 3.4 List of Data Sources

4 GLOBAL PEPTIDE CANCER VACCINE MARKET OUTLOOK

  • 4.1 Overview
  • 4.2 Market Dynamics
    • 4.2.1 Drivers
    • 4.2.2 Restraints
    • 4.2.3 Opportunities
  • 4.3 Porters Five Force Model
  • 4.4 Value Chain Analysis

5 GLOBAL PEPTIDE CANCER VACCINE MARKET, BY TECHNOLOGY

  • 5.1 Overview
  • 5.2 Recombinant Cancer Vaccines
  • 5.3 Whole-cell Cancer Vaccines
  • 5.4 Viral Vector and DNA Cancer Vaccines
  • 5.5 Other Technologies (Dendritic Cells, Antigen, etc.)

6 GLOBAL PEPTIDE CANCER VACCINE MARKET, BY APPLICATION

  • 6.1 Overview
  • 6.2 Breast Cancer
  • 6.3 Lung Cancer
  • 6.4 Melanoma
  • 6.5 Prostate Cancer
  • 6.6 Others

7 GLOBAL PEPTIDE CANCER VACCINE MARKET, BY TYPE

  • 7.1 Overview
  • 7.2 Personalized Peptide Vaccine
  • 7.3 Peptide-Pulsed Dendritic Cancer Vaccine
  • 7.4 Peptide Cocktail Type
  • 7.5 Multivalent Peptide Vaccine
  • 7.6 Others

8 GLOBAL PEPTIDE CANCER VACCINE MARKET, BY GEOGRAPHY

  • 8.1 Overview
  • 8.2 North America
    • 8.2.1 U.S.
    • 8.2.2 Canada
    • 8.2.3 Mexico
  • 8.3 Europe
    • 8.3.1 Germany
    • 8.3.2 U.K.
    • 8.3.3 France
    • 8.3.4 Rest of Europe
  • 8.4 Asia Pacific
    • 8.4.1 China
    • 8.4.2 Japan
    • 8.4.3 India
    • 8.4.4 Rest of Asia Pacific
  • 8.5 Rest of the World
    • 8.5.1 Latin America
    • 8.5.2 Middle East and Africa

9 GLOBAL PEPTIDE CANCER VACCINE MARKET COMPETITIVE LANDSCAPE

  • 9.1 Overview
  • 9.2 Company Market Ranking
  • 9.3 Key Development Strategies

10 COMPANY PROFILES

  • 10.1 OSE Immunotherapeutics
    • 10.1.1 Overview
    • 10.1.2 Financial Performance
    • 10.1.3 Product Outlook
    • 10.1.4 Key Developments
  • 10.2 GlaxoSmithKline PLC
    • 10.2.1 Overview
    • 10.2.2 Financial Performance
    • 10.2.3 Product Outlook
    • 10.2.4 Key Developments
  • 10.3 Moderna Inc.
    • 10.3.1 Overview
    • 10.3.2 Financial Performance
    • 10.3.3 Product Outlook
    • 10.3.4 Key Developments
  • 10.4 Merck and Co Inc.
    • 10.4.1 Overview
    • 10.4.2 Financial Performance
    • 10.4.3 Product Outlook
    • 10.4.4 Key Developments
  • 10.5 F Hoffmann-La Roche AG
    • 10.5.1 Overview
    • 10.5.2 Financial Performance
    • 10.5.3 Product Outlook
    • 10.5.4 Key Developments
  • 10.6 BrightPath Biotherapeutics
    • 10.6.1 Overview
    • 10.6.2 Financial Performance
    • 10.6.3 Product Outlook
    • 10.6.4 Key Developments
  • 10.7 Boston Biomedical
    • 10.7.1 Overview
    • 10.7.2 Financial Performance
    • 10.7.3 Product Outlook
    • 10.7.4 Key Developments
  • 10.8 VAXON Biotech
    • 10.8.1 Overview
    • 10.8.2 Financial Performance
    • 10.8.3 Product Outlook
    • 10.8.4 Key Developments
  • 10.9 Generex Biotechnology
    • 10.9.1 Overview
    • 10.9.2 Financial Performance
    • 10.9.3 Product Outlook
    • 10.9.4 Key Developments
  • 10.10 ISA Pharmaceuticals
    • 10.10.1 Overview
    • 10.10.2 Financial Performance
    • 10.10.3 Product Outlook
    • 10.10.4 Key Developments

11 KEY DEVELOPMENTS

  • 11.1 Product Launches/Developments
  • 11.2 Mergers and Acquisitions
  • 11.3 Business Expansions
  • 11.4 Partnerships and Collaborations

12 Appendix

  • 12.1 Related Research